PMID- 37519893
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230801
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Electronic)
IS  - 1664-8021 (Linking)
VI  - 14
DP  - 2023
TI  - Oxidative stress genes define two subtypes of triple-negative breast cancer with 
      prognostic and therapeutic implications.
PG  - 1230911
LID - 10.3389/fgene.2023.1230911 [doi]
LID - 1230911
AB  - Introduction: Oxidative stress (OS)-related genes have been confirmed to be 
      closely related to the prognosis of triple-negative breast cancer (TNBC) 
      patients; despite this fact, there is still a lack of TNBC subtype strategies 
      based on this gene guidance. Here, we aimed to explore OS-related subtypes and 
      their prognostic value in TNBC. Methods: Data from The Cancer Genome Atlas 
      (TCGA)-TNBC and Sequence Read Archive (SRA) (SRR8518252) databases were 
      collected, removing batch effects using a combat method before analysis. 
      Consensus clustering analysis identified two OS subtypes (clusters A and B), with 
      cluster A showing a better prognosis. Immune infiltration characteristics were 
      analyzed using ESTIMATE and single-sample gene set enrichment analysis (ssGSEA) 
      algorithms, revealing higher ImmuneScore and ESTIMATEscore in cluster A. 
      Tumor-suppressive immune cells, human leukocyte antigen (HLA) genes, and three 
      immune inhibitors were more prevalent in cluster A. Results: An eight-gene 
      signature, derived from differentially expressed genes, was developed and 
      validated as an independent risk factor for TNBC. A nomogram combining the risk 
      score and clinical variables accurately predicted patient outcomes. Finally, we 
      also validated the classification effect of subtypes using hub markers of each 
      subtype in the test dataset. Conclusion: Our study reveals distinct molecular 
      clusters based on OS-related genes to better clarify the reactive oxygen species 
      (ROS)-mediated progression and the crosstalk between the ROS and tumor 
      microenvironment (TME) in this heterogenetic disease, and construct a risk 
      prognostic model which could provide more support for clinical treatment 
      decisions.
CI  - Copyright (c) 2023 Liu, Xu, Feng, Kahlert, Du, Torres-de la Roche, Xu, Shi and 
      Meng.
FAU - Liu, Shenting
AU  - Liu S
AD  - Department of Oncology Medicine, Hainan Cancer Hospital, Haikou, Hainan, China.
FAU - Xu, He
AU  - Xu H
AD  - Department of Thyroid and Breast Surgery, Xuzhou Municipal Hospital Affiliated to 
      Xuzhou Medical University, Xuzhou, China.
FAU - Feng, Ying
AU  - Feng Y
AD  - Department of Thyroid and Breast Surgery, Xuzhou Municipal Hospital Affiliated to 
      Xuzhou Medical University, Xuzhou, China.
FAU - Kahlert, Ulf D
AU  - Kahlert UD
AD  - Molecular and Experimental Surgery, University Clinic for General- Visceral- 
      Vascular- and Trans-Plantation Surgery, Medical Faculty University Hospital 
      Magdeburg, Otto-von Guericke University Magdeburg, Germany.
FAU - Du, Renfei
AU  - Du R
AD  - Molecular and Experimental Surgery, University Clinic for General- Visceral- 
      Vascular- and Trans-Plantation Surgery, Medical Faculty University Hospital 
      Magdeburg, Otto-von Guericke University Magdeburg, Germany.
FAU - Torres-de la Roche, Luz Angela
AU  - Torres-de la Roche LA
AD  - University Hospital for Gynecology, Pius-Hospital, University Medicine Oldenburg, 
      Carl von Ossietzky University Oldenburg, Oldenburg, Germany.
FAU - Xu, Kai
AU  - Xu K
AD  - Department of Thyroid and Breast Surgery, Xuzhou Municipal Hospital Affiliated to 
      Xuzhou Medical University, Xuzhou, China.
FAU - Shi, Wenjie
AU  - Shi W
AD  - Molecular and Experimental Surgery, University Clinic for General- Visceral- 
      Vascular- and Trans-Plantation Surgery, Medical Faculty University Hospital 
      Magdeburg, Otto-von Guericke University Magdeburg, Germany.
FAU - Meng, Fanshuai
AU  - Meng F
AD  - Translational and Trauma Surgery Laboratory, University of Ulm, Ulm, Germany.
LA  - eng
PT  - Journal Article
DEP - 20230713
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC10372428
OTO - NOTNLM
OT  - immunotherapy
OT  - molecular subtype
OT  - oxidative stress
OT  - relapse-free survival
OT  - triple-negative breast cancer
OT  - tumor microenvironment
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/07/31 06:42
MHDA- 2023/07/31 06:43
PMCR- 2023/07/13
CRDT- 2023/07/31 04:41
PHST- 2023/05/29 00:00 [received]
PHST- 2023/06/30 00:00 [accepted]
PHST- 2023/07/31 06:43 [medline]
PHST- 2023/07/31 06:42 [pubmed]
PHST- 2023/07/31 04:41 [entrez]
PHST- 2023/07/13 00:00 [pmc-release]
AID - 1230911 [pii]
AID - 10.3389/fgene.2023.1230911 [doi]
PST - epublish
SO  - Front Genet. 2023 Jul 13;14:1230911. doi: 10.3389/fgene.2023.1230911. eCollection 
      2023.